The Trump administration's Department of Justice issued a final order on April 22, 2026, rescheduling FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective upon Federal Register publication around April 28. This executive action, signed by Acting Attorney General Todd Blanche, unlocks federal protections and tax benefits like Section 280E relief for qualifying medical operations, with the DEA now accepting registration applications as of late April. Broader rescheduling of botanical marijuana awaits an expedited DEA administrative hearing starting June 29, 2026, amid ongoing GOP congressional efforts to block further changes despite the administration's move. Traders weigh procedural timelines, potential legal challenges, and political pressures in assessing resolution paths.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$750,045 Vol.
31 mar 2026
30 de junio
4%
31 de diciembre
36%
$750,045 Vol.
30 de junio
$331,418 Vol.
4%
31 de diciembre
$153,745 Vol.
36%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration's Department of Justice issued a final order on April 22, 2026, rescheduling FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective upon Federal Register publication around April 28. This executive action, signed by Acting Attorney General Todd Blanche, unlocks federal protections and tax benefits like Section 280E relief for qualifying medical operations, with the DEA now accepting registration applications as of late April. Broader rescheduling of botanical marijuana awaits an expedited DEA administrative hearing starting June 29, 2026, amid ongoing GOP congressional efforts to block further changes despite the administration's move. Traders weigh procedural timelines, potential legal challenges, and political pressures in assessing resolution paths.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Feb 7, 2026, 5:04 PM ET
Volumen
$750,045Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration's Department of Justice issued a final order on April 22, 2026, rescheduling FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective upon Federal Register publication around April 28. This executive action, signed by Acting Attorney General Todd Blanche, unlocks federal protections and tax benefits like Section 280E relief for qualifying medical operations, with the DEA now accepting registration applications as of late April. Broader rescheduling of botanical marijuana awaits an expedited DEA administrative hearing starting June 29, 2026, amid ongoing GOP congressional efforts to block further changes despite the administration's move. Traders weigh procedural timelines, potential legal challenges, and political pressures in assessing resolution paths.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$750,045Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Trump administration's Department of Justice issued a final order on April 22, 2026, rescheduling FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective upon Federal Register publication around April 28. This executive action, signed by Acting Attorney General Todd Blanche, unlocks federal protections and tax benefits like Section 280E relief for qualifying medical operations, with the DEA now accepting registration applications as of late April. Broader rescheduling of botanical marijuana awaits an expedited DEA administrative hearing starting June 29, 2026, amid ongoing GOP congressional efforts to block further changes despite the administration's move. Traders weigh procedural timelines, potential legal challenges, and political pressures in assessing resolution paths.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes